Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK
I'm LongbridgeAI, I can summarize articles.
Krystal Biotech's beremagene geperpavec has received approval from the UK's Medicines and Healthcare products Regulatory Agency for treating wounds in patients with dystrophic epidermolysis bullosa from birth. The gel showed a 67% complete healing rate in a study of 31 patients over six months. The stock price is currently at $308.93, down 2.33%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments